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Clinical review
Recent advances
Paediatric anaesthesia
S C S Russell, E Doyle
About one quarter of the population are aged under
15 years and many of them will require anaesthesia
and surgery. Several recent developments have
contributed to making anaesthesia for children easier,
safer, and more pleasant for the child and parents.
Topical cutaneous anaesthesia
One of the most unpleasant procedures for children in
hospital is insertion of a venous cannula for induction
of anaesthesia, taking blood samples, or administering
fluid and drugs. To try to reduce the pain associated
with the procedure a topically active local anaesthetic
preparation is applied such as Emla cream (a mixture
of 2.5 mg/ml of lignocaine and 2.5 mg/ml of
prilocaine). To work properly Emla cream has to be
applied at least an hour before the procedure,1 2 which
means it is not suitable for emergency and some day
case patients. Even when applied for 60 minutes it is
effective in only 65% of children,3 although this
proportion rises if it is left in place for 90›120 minutes.4
Emla cream also causes vasoconstriction at the site of
application, which can make venepuncture difficult.5
The recent development and licensing of a topical
cream made with the local anaesthetic amethocaine
has greatly improved topical anaesthesia. Amethocaine
has a much higher lipid solubility than Emla and pen›
etrates the stratum corneum, the main barrier to
absorption of drugs through the skin, with comparative
ease. A gel containing 4% amethocaine has been
shown to provide analgesia for venous cannulation in
over 80% of children compared with 66% of children
who had Emla cream applied for the same period.6
This makes amethocaine particularly useful in
outpatient day case surgery. Amethocaine has also
been found to cause erythema and vasodilatation at
the site of application, which may facilitate venous
cannulation.7
Sevoflurane
One of the ways in which paediatric anaesthesia differs
from adult anaesthesia is that inhalational induction is
used much more commonly. The characteristics of the
volatile anaesthetic agent used are important. It needs
to induce anaesthesia quickly, have a low incidence of
complications such as coughing, laryngospasm, and
hypoxia during induction, and allow rapid recovery.
Until recently halothane was the most commonly used
agent, and this generally results in smooth, trouble free
inductions. However, a new agent, sevoflurane, is now
available in Britain which has very low solubility in
blood (the blood›gas partition coefficient is 0.47
compared with 2.1 for halothane). Studies have shown
that it induces anaesthesia more rapidly than
halothane,8›12 and it is also eliminated more quickly
from the blood, producing a faster recovery.10›14
Sevoflurane has a pleasant smell and is the least
irritant of the volatile agents to the respiratory tract.
There is a low incidence of respiratory tract irritation
during its use.15 16 It produces similar degrees of
myocardial depression and hypotension to equipotent
concentrations of halothane in children10 and less sen›
sitisation of the myocardium to catecholamines.17 The
degree of respiratory depression is similar to that pro›
duced by halothane at equipotent concentrations.18 19
Halothane hepatitis
Repeated administration of halothane occasionally
results in halothane hepatitis. This can develop into
hepatic necrosis, which may be fatal. The condition is
probably caused by hapten formation with the
trifluoroacetic acid metabolite of halothane and the
subsequent production of antibodies and free radicals
toxic to the liver. Halothane hepatitis is less common in
children than adults20 21 but is nevertheless important.22
Since sevoflurane is metabolised to a much lesser
extent than halothane (3.3% compared with 20%) and
the metabolite trifluoroacetic acid is not produced,23
the problem of halothane hepatitis should be sig›
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nificantly reduced or eliminated. The degree of hapten
formation with the sevoflurane metabolite hexafluoro›
isopropanol is much less than with trifluoroacetic acid
and no free radical production has been found.16 Only
four cases of hepatotoxicity attributable to sevoflurane
have been reported in over two million
administrations.24
The low toxicity of sevoflurane makes it particularly
useful in children since they often require repeated
inhalational anaesthesia for multiple procedures
carried out close together. The other available volatile
anaesthetic agents, enflurane and isoflurane, are not
suitable for routine inhalational induction of anaesthe›
sia and are associated with a higher incidence of peri›
operative complications than halothane.25 26 A drug
which combines rapid trouble free induction of anaes›
thesia with minimal risk of hepatic damage during
repeated administrations is thus a welcome advance in
safety.
Caudal epidural blockade
Epidural analgesia using a single injection of local
anaesthetic to the epidural space via the caudal
approach combines the advantages of a simple
technique with a high success rate and is one of the
commonest local anaesthetic techniques used in
children. The technique has a wide range of indications
in paediatric practice including orchidopexy, circumci›
sion, and inguinal herniotomy as well as lower limb
and pelvic orthopaedic surgery and lower abdominal
surgery in neonates and infants. Its main disadvantage
is the short duration of action, and even long acting
local anaesthetic drugs such as bupivacaine will reliably
provide analgesia for only three to four hours.27
Various additives to local anaesthetic solutions have
been used to try to prolong the duration of caudal
analgesia provided by a single injection. Opioids mixed
with the local anaesthetic are effective at prolonging
the duration of caudal epidural analgesia28 but
concerns about late respiratory depression mean that
they can be used only for patients who are going to be
nursed in a high dependency setting.
Alternative additives which are currently being
investigated include clonidine and ketamine. Clonidine
is an á2 adrenergic receptor agonist, a class of drug
which is widely used in medicine and anaesthesia as an
antihypertensive, sedative, premedicant, and analgesic.
Clonidine probably induces analgesia when admin›
istered epidurally by stimulating the descending
noradrenergic medullospinal pathways. These inhibit
the release of nociceptive neurotransmitters in the
dorsal horn of the spinal cord. Ketamine hydrochlo›
ride is widely used for anaesthesia and analgesia in
children. It acts as an antagonist at the subset of gluta›
mate receptors stimulated by the agonist N›methyl
d›aspartate (NMDA). NMDA receptors are found
throughout the central nervous system including the
lumbar spinal cord. As well as producing analgesia
after systemic administration ketamine exerts pro›
found analgesic actions at the spinal cord level in ani›
mal preparations.29 30 This feature, together with the
minimal respiratory depressant effects of ketamine, has
stimulated clinical interest in the epidural administra›
tion of ketamine to provide postoperative analgesia.
Clonidine and ketamine have both been shown
to prolong the duration of the local anaesthetic
bupivacaine when used to provide caudal epidural
analgesia. The median duration of caudal epidural
analgesia with 0.25% bupivacaine is prolonged from
3›4 hours to 9›16 hours when 1›2 ìg/kg of clonidine is
added to the local anaesthetic solution.31 32 Similarly,
ketamine combined with 0.25% bupivacaine signifi›
cantly prolongs the median duration of a single shot
caudal epidural blockade to 12.5 hours.33 34 The
optimal dose of ketamine for prolonging caudal
epidural blockade in children has been shown to be 0.5
mg/kg.35 No differences have been found between chil›
dren receiving caudal epidural clonidine or ketamine
and control groups in the occurrence of side effects
such as significant haemodynamic changes, respiratory
depression, motor block, urinary retention, or postop›
erative sedation.31›35
Until new longer acting local anaesthetics that can
selectively block sensory rather than motor and
autonomic fibres are developed the use of additives is
likely to continue. Clonidine and ketamine offer the
potential to prolong the duration of single shot caudal
injections with minimal risk of side effects. Further
studies are needed, however, to compare the optimum
regimens of these two additives and to obtain a more
complete picture of their benefits and the incidence of
side effects in children.
Conclusion
The three developments described here illustrate the
ways in which paediatric anaesthesia differs signifi›
cantly from practice in adults, where none of the above
issues are as important. The need for and use of topical
cutaneous analgesia is rare in adults and inhalational
induction of anaesthesia is also unusual. Caudal
epidural analgesia has far fewer indications in adults
than children, although the additives described may
also prove useful in epidural infusions of local
anaesthetic and subarachnoid (spinal) anaesthesia.
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Science, medicine, and the future
Role of molecular cell biology in understanding disease
John Savill
Abstract
Molecular techniques have revolutionised our
knowledge of cell and tissue function in both health
and disease. We already have new and powerful
treatments based on an understanding of
communication between cells by messenger
molecules called cytokines. Furthermore, there is
great therapeutic promise in defining molecules
which regulate cell adhesion, motility, proliferation,
survival, and death. Rational manipulation of cell and
tissue function for therapeutic ends may be much
closer than you think.
Introduction
When I went to medical school in 1975 I did not lie
awake at night thinking about cell biology. Indeed, I
often cat napped as my teachers struggled to instil an
interest in the structure and function of cells through
histology. But 22 years later I regularly lose sleep excit›
edly planning experiments in molecular cell biology.
My change in attitude relates to the fashionable and
often overused prefix “molecular”; advances in
molecular biology and protein chemistry over the past
15 years have fuelled a revolution in the dissection and
manipulation of cell and tissue function. This article
focuses on a few “hot” topics in molecular cell biology
which have far reaching potential in medicine.
Cytokines and cytokine based treatments
In 1975 the messengers in cell communication were
mainly elusive factors with confusing names based on
activities defined in bioassays. Now these intercellular
messengers have found an everyday use in medicine.
For example, in haematology and oncology it is now
routine to treat life threatening neutropenia with
granulocyte colony stimulating factor. This polypep›
tide messenger or cytokine stimulates the bone
marrow to produce and release neutrophil granulo›
cytes needed in defence against infection.
What has changed in the last 20 years? Not the ter›
minology, I fear. The unsystematic and confusing
nomenclature of cytokines still depends on how or
when the activity was described or the agent was
biochemically characterised. The interleukins, now
numbered in temporal sequence of identification, are
cytokines with many cellular targets but the name
reflects their discovery in leucocyte›leucocyte interac›
tions. Interferons regulate many cell functions but were
initially identified in studies of viral replication in cells.
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Growth factors, cytokines which stimulate cell division
rather than enlargement, include the potent mitogen
platelet derived growth factor, which is now known to
be produced by many cell types other than platelets.
Although transforming growth factor á stimulates
epithelial cell division, transforming growth factor â
has a different structure and wide ranging properties
including inhibition of cell division. Indeed, accidents
of discovery have awarded a single cytokine different
names. Tumour necrosis factor á, a polypeptide initially
defined as killing tumour cells in culture, was also
called cachectin because of its catabolic properties in
infection and cancer, but its main role seems to be in
mobilising the acute inflammatory response.
The advances in cytokine biology have been in
protein chemistry and molecular biology. New, sophis›
ticated chromatographic techniques allow the separa›
tion of secreted proteins such as cytokines on the basis
of size and electrostatic charge. Minute quantities of
isolated protein can be “microsequenced” to define
short stretches of the amino acid backbone. It is then
possible to synthesise short lengths of nucleotide bases
that encode the amino acid sequence and use them to
clone the cDNA for the cytokine (fig1). Defining the
nucleotide sequence of a full length cDNA allows pre›
diction of the amino acid sequence of the whole
protein, assignment to a particular cytokine family, and
modelling of three dimensional structure. For exam›
ple, the potent pro›inflammatory cytokine tumour
necrosis factor á is a member of the graphically named
“jelly roll” family.
Furthermore, the cDNA can be incorporated into
viral based vectors which are then introduced into
“workhorse” cell cultures that produce the cytokine
protein product for harvest. The action of the pure
cytokine can then be studied in culture or animal mod›
els. Similar information can be obtained by the
converse approach of inhibiting cytokine function with
neutralising antibodies generated by immunising
animals with pure cytokine. Such antibodies are also
invaluable in detecting and quantifying cytokine
expression in biological solutions such as plasma, in
histological sections, and (in experimental settings)
in homogenised tissue specimens—complementing
techniques based on measuring mRNA expression
(table 1).
Cytokine based treatments will be particularly
important in inflammatory, immune, and infective
conditions. Human rheumatoid arthritis can be
temporarily ameliorated with neutralising antibody to
tumour necrosis factor á, and there is every prospect of
attaining similar improvements with physiological,
non›immunogenic agents such as soluble tumour
necrosis factor receptor. Given the importance of
tumour necrosis factor á in mediating tissue injury asso›
ciated with septic shock, such inhibitors may also prove
useful in adjunctive treatment of severe infections.
Indeed, as we understand more of the endogenous
checks and balances of cytokine action we can look for›
ward to anti›inflammatory treatments based on mol›
ecules such as the interleukin 1â receptor antagonist, a
naturally occurring cytokine which blocks receptors for
interleukin 1â during resolution of inflammation.
Adhesion molecules and cell matrix
interactions
Cell biologists now have a remarkably detailed under›
standing of the adhesion molecules that mediate
emigration of leucocytes from the blood across the wall
of the postcapillary venule and into the tissues. Cell
surface adhesion molecules are the Velcro which hold
cells and tissues together. Those expressed by
leucocytes and endothelial cells are special in that their
stickiness is regulated by pro›inflammatory messenger
molecules such as cytokines (fig 2).
Anti›inflammatory treatments based on selective
inhibition of endothelial›leucocyte adhesion molecules
are about to be tested in humans. They have already
proved effective in blocking inflammatory responses in
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Fig 1 Identifying a novel protein by cloning from a cDNA library.
A cDNA library is made by harvesting mRNAs from a tissue of
interest. These are reverse transcribed to generate a collection or
library of cDNAs which represent genes expressed in the tissue.
Purification and amino acid sequencing of a protein fragment
allows prediction and synthesis of the oligonucleotide which would
encode the fragment. This can be used as a “hook” to “fish” for
cDNA strands with complementary sequence and to retrieve, copy
(clone), and sequence a full length cDNA allowing prediction of the
full protein amino acid sequence
Table 1 Methods of detecting gene expression
Messenger RNA Protein
In homogenised tissue
specimens
Northern blotting reverse transcriptase
polymerase chain rection (very sensitive)
Western (immuno) blotting
In histological sections In situ hybridisation
In situ polymerase chain
reaction (very sensitive)
Immunohistochemistry
In solution Not applicable Enzyme linked immunosorbent
assay
Radioimmunoassay
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animal models. Furthermore, these approaches may
help to prevent bloodborne metastasis of cancer cells,
which may occur by similar adhesive mechanisms.
Adhesion molecules are also important conduits of
information between the extracellular matrix and cells.
The extracellular matrix is composed of proteins and
proteoglycans which surround cells in solid organs and
form basement membranes in epithelia. It is now clear
that the extracellular matrix can greatly affect attached
cells—for example, the extracellular matrix protein
laminin is critical for differentiation of alveoli in the
lactating breast. Extracellular matrix proteins can also
signal survival of cells, holding at bay otherwise inevi›
table cell death by the physiological cell suicide
programme of apoptosis. By contrast with accidental
cell death or necrosis, apoptosis is a precisely regulated
and programmed cell death which amounts to suicide
because the cell activates a cascade of death enzymes
which kill the cell and mark it for safe clearance by
phagocytes. Excitingly, antibody mediated blockade of
an extracellular matrix receptor on new blood vessels
growing into tumours results in apoptosis of vascular
cells and tumour involution.
Cells of many lineages, including tissue cells such as
fibroblasts, can also remodel extracellular matrix by
secreting matrix metalloproteinases, protein degrading
enzymes which digest extracellular matrix providing
they are supplied with calcium or other metal ions.
This can, for example, enable cells to migrate through
tissues. Consequently, it should not be surprising that
inhibitors of matrix metalloproteinases are showing
promise as antimetastatic agents in cancer. Conversely,
naturally occurring inhibitors of extracellular matrix
degrading enzymes could be beneficially blocked to
prevent postinflammatory scarring.
Cell proliferation, survival, and death
Molecular cell biology could have particularly impor›
tant implications in cancer. In this article it is sufficient
to highlight the important role in carcinogenesis of
somatic mutations (that is, arising after fertilisation of
an egg). These mutations bring about increased
expression of a set of oncogenes, which encode
proteins involved in cell proliferation. Examples
include erb, which encodes a cell surface growth factor
receptor, and c›myc, which gives rise to a nuclear pro›
tein essential for cell division.
However, disregulated expression of bcl›2, a
ubiquitous gene first characterised in follicular B cell
lymphoma, leads to cell accumulation by promoting
cell survival rather than cell proliferation. Bcl›2 protein
is a potent inhibitor of most stimuli which induce
apoptosis, the programmed and physiological form of
cell death that normally counterbalances cell birth by
mitosis. A disrupted balance of cell survival and cell
death by apoptosis may be important in many diseases
(box). For example, an important application may be in
neurodegenerative diseases such as spinal muscular
atrophy. Molecular geneticists discovered that the gene
mutated in this condition normally encodes a molecule
similar to an inhibitor of an apoptosis protein first
found in insects. This protein proved to be the index
member of a ubiquitous family of survival proteins and
is a candidate treatment for spinal muscular atrophy.
Indeed, other nerve cell survival factors are being
tested as treatments for commoner conditions
associated with unscheduled neuronal death, such as
Parkinson’s disease.
Designer proteins
New skills in molecular and cell biology can be
combined to make cultured cells synthesise altered
proteins with therapeutically desirable properties. As
described in preceding articles, site directed mutagen›
esis can be used to alter cDNAs so that altered proteins
are synthesised when cells are transfected with a viral
based expression vector bearing the new cDNA. An
example is soluble complement receptor 1, a truncated
form of a protein which normally spans cell
membranes. Normal or “wild type” complement
receptor 1 binds and inactivates injurious pro›
inflammatory peptides generated by the complement
cascade. Soluble complement receptor 1, which was
mutated so that it lacks the membrane›spanning
domain, can be harvested from cellular expression sys›
tems. After intravenous injection the protein circulates
and can be used as a potent anti›inflammatory agent.
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Fig 2 Molecular mechanisms of inflammation. Inflammatory mediators generated by
tissue injury act on both leucocytes and endothelial cells. Leucocytes are initially attached
to and rolled along the vessel wall, mediated by receptors of the selectin family and their
counter receptors of the mucin family. Next, leucocyte receptors of the integrin family
mediate firm adhesion and spreading of leucocytes on endothelial cells by binding
endothelial cell receptors with structural similarity to the immunoglobulins. A particular
receptor in this family (platelet›endothelial cell adhesion molecule 1) mediates movement
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Microbiology and immunology
Molecular cell biology has many applications in the
prevention and treatment of infectious disease.
Defining how micro›organisms adhere to and breach
cellular barriers will provide new strategies for
treatment. For example, both rhinoviruses and
erythrocytes parasitised with malaria can adhere to
intercellular adhesion molecule 1, which usually medi›
ates cell›cell interaction in inflammatory and immune
responses. The potential usefulness of blocking such
adhesion is shown by recent data on the leucocyte
â›chemokine receptor type 5; a chemokine is a
cytokine which attracts leucocytes. This receptor is
used by HIV›1 to infect leucocytes; people with an
inherited deficiency in chemokine receptor type 5
resist HIV›1 invasion of leucocytes and may live for
many years without developing AIDS.
Vaccine development has also received a boost
from the ability to construct and express designer pro›
teins. Many proteins have evolved by evolutionary
shuffling of building blocks called domains. It is now
possible to shuffle the pack further almost at will by
fusing cDNAs which encode protein domains. Fusion
proteins in which bacterial protein domains are
combined with several copies of a human complement
protein domain greatly enhance the immunogenicity
of the bacterial material.
Choosing proteins on which to base new vaccines
may become much easier because of improved knowl›
edge of the molecular cell biology of the immune
response. Antigen presenting cells activate protective
immune responses by processing ingested antigenic
proteins into short peptides which are then presented
at the surface of the cell. The antigenic peptide is
displayed to T lymphocytes by being fixed in the "jaws”
of major histocompatibility complex molecules on the
surface of antigen presenting cells. The presented pep›
tides can be isolated and sequenced or characterised
by screening candidate peptides for their ability to pro›
mote reassociation in vitro of the isolated subunits of
major histocompatibility complex molecules. These
last techniques have been used to identify the malarial
protein liver stage antigen 1 as a vaccine candidate.
Peptides from the protein bind the major histocompat›
ibility complex molecule B53, which seems protective
as people with severe malaria possess B53 less often
than controls.
Lastly, molecular techniques for manipulating cell
function have revolutionised the discipline of immunol›
ogy, which has pioneered developments in cell adhesion,
cytokine biology, and cell death. New approaches to
treating autoimmune diseases such as rheumatoid
arthritis will be discussed in future articles in this series.
Conclusion
I hope you can understand why molecular cell biology
excites me. Understanding the molecular basis of cell
and tissue function will provide insights into the
pathogenesis of disease. The discipline has, and will,
bring basic science to the bedside in the form of new
and effective treatments.
Lesson of the week
Prevalence of concomitant disease in patients with iron
deficiency anaemia
Simon H Till, Michael J Grundman
How to investigate patients presenting with iron
deficiency anaemia is a matter of debate. Undoubtedly
one of the commonest lethal, but potentially curable,
causes is colonic carcinoma, the second most common
cancer in both men and women in the West. Despite
this, the colon may not be investigated if an acceptable
cause for the anaemia has been found on upper
gastrointestinal investigations.
Clinically important concomitant disease, such as
benign upper gastrointestinal disease associated with
colonic cancer, has been reported in up to 7% of anae›
mic patients,1›3 yet combined upper and lower
gastrointestinal investigations are carried out in only a
minority of cases with iron deficiency anaemia.4
Patients, methods, and results
We examined the records of 89 consecutive patients
referred with iron deficiency anaemia and at least two
positive faecal occult blood results between 1989 and
1992. Iron deficiency anaemia was defined by a
haemoglobin concentration of < 110 g/l in association
with a mean corpuscular volume of < 80 fl and either a
serum ferritin concentration of < 10 mg/l or an appro›
priate response to iron supplementation. Patients were
either followed up or their case notes were reviewed or
their general practitioner was contacted. The case
notes of all patients were reviewed in July 1995, a mini›
mum of three years after initial presentation. We iden›
tified “acceptable” causes for the anaemia in 67
patients (table 1). Six patients had concomitant disease;
in three potentially curative surgery was delayed
because of the gastroscopy findings (box). Cases
1›7—and a more recent case (8)—show the importance
of not ascribing the cause of iron deficiency anaemia to
a lesion in the oesophagus, stomach, or duodenum
unless the colon has been investigated.
Discussion
The prevalence of colonic cancer among patients pre›
senting with iron deficiency anaemia varies consider›
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ably, with outpatient studies suggesting rates of
4›11%.1 3 5 6 We diagnosed malignant disease of the
colon in 14 (15%) patients. Of the 13 patients who
were initially found to have colonic cancer, six (46%)
had “acceptable” upper gastrointestinal causes for
their anaemia. The incidence of colonic cancer
increases with age, 94% occurring in patients over the
age of 50.7 All our patients were aged over 60, and all
cancers were proximal to the splenic flexure. The
higher prevalence of colonic cancer in our audit might
be attributed to our use of faecal occult blood loss as a
selection criterion, in contrast to other studies,1 3 5 6 but
the role of faecal occult blood testing in iron
deficiency remains to be evaluated.
The risks of not investigating the colon have been
further emphasised by a recent audit of the investiga›
tion and outcome of iron deficiency anaemia.4 Long
term follow up identified two patients (at 21 and 18
months) with advanced carcinoma of the colon.
Neither patient had had colonic investigations at the
time of initial presentation.
Of the six patients with concomitant disease, three
had potentially curative surgery delayed because of
their gastroscopy findings (cases 1, 2, and 6). The delay
in the cases 2 and 6 was particularly lengthy (10 and
12 months, respectively). We suspect that had colonic
investigations been carried out at the time of initial
presentation, the diagnosis would almost certainly
have been made.
The potential for delay in diagnosing proximal
colonic cancer was first raised in 1969.8 Fagan
reported that 10 out of 96 cancers of the right side of
the colon were initially misdiagnosed as an upper gas›
trointestinal lesion on the basis of a positive finding on
barium meal examination. A more recent study
concluded that a delay in referral for investigation was
the main avoidable reason for delay in diagnosis
rather than the finding of an upper gastrointestinal
lesion.9
Symptoms did not correlate well with the final
diagnosis. This has been shown before.1 2 3 10 Of the six
patients with concomitant disease, three had upper
gastrointestinal symptoms while none had proximal
colonic symptoms. Only Rockey et al reported that
colonic symptoms predicted colonic disease.5
Follow up of patients in 1995, at least three years
after their initial investigations, has not shown serious
gastrointestinal disease in patients discharged after
negative results on gastroscopy, duodenal biopsy, and
barium enema, confirming that this is a safe, limited
approach to the investigation of patients presenting
with iron deficiency anaemia.11 Duodenal biopsy is a
simple process during gastroscopy, and many series
Table 1 Results of investigations (89 patients)
Diagnosis No of patients
Oesophagitis 14
Colonic cancer 13
Gastric erosion 13
Erosive gastritis 7
Benign colonic adenomatous polyp 6
Duodenal ulcer 5
Gastric cancer 3
Coeliac disease 3
Colonic angiodysplasia 2
Gastric adenomatous polyp 2
Ulcerative colitis 2
Oesophageal cancer 1
Gastric ulcer 1
Barrett’s ulcer 1
Gastric angiodysplasia 1
Crohn’s disease 1
No diagnosis 14
Concomitant disease in eight cases
of iron deficiency anaemia
Case 1—65 year old man; haemoglobin 83 g/l;
no gastrointestinal symptoms. Deep Barrett’s
ulcer shown by gastroscopy. Iron and
ranitidine resolved ulcer and anaemia. Latter
recurred after stopping treatment. Barium
enema six months later showed caecal mass.
Right hemicolectomy for Dukes’ C caecal
carcinoma.
Case 2—67 year old man; increasing dysphagia;
haemoglobin 68 g/l. Previous benign
oesophageal stricture. Treated with iron and
omeprazole for severe oesophagitis. Anaemia
recurred 10 months later; barium enema
indicated caecal mass. Palliative hemicolectomy
for annular Dukes’ C caecal carcinoma.
Case 3—72 year old man; haemoglobin 77 g/l;
minimal fresh rectal bleeding. Erosive gastritis
at gastroscopy and caecal mass on barium
enema. Right hemicolectomy for Dukes’ B
caecal carcinoma six weeks later.
Case 4—79 year old woman; haemoglobin 107
g/l; no gastrointestinal symptoms. Erosive
gastritis at gastroscopy and “apple core” lesion
in ascending colon on barium enema. Right
hemicolectomy for Dukes’ B carcinoma one
month later.
Case 5—69 year old man; haemoglobin 104 g/l;
epigastric discomfort. Grade 1 oesophagitis
and ascending colon filling defect. Right
hemicolectomy for Dukes’ B carcinoma.
Case 6—75 year old man; haemoglobin 105 g/l;
emergency admission; history of
haematemesis, melaena, iron deficiency
anaemia. Oesophageal ulcer treated with
omeprazole. Barium enema for recurrent
anaemia showed ascending colonic mass;
Dukes’ C carcinoma confirmed at surgery.
Case 7—70 year old woman; abdominal mass
confirmed as Dukes’ B caecal carcinoma.
Investigated seven years earlier for iron
deficiency anaemia: normal results; iron
treatment resolved anaemia. This recurred
three years later; gastroscopy and colonoscopy
to hepatic flexure only were normal. Repeat
barium enema advised but declined by patient.
Case 8—68 year old man; reflux helped by
ranitidine; haemoglobin 67 g/l. Chronic
duodenal ulcer on gastroscopy and mass at
hepatic flexure on barium enema examination.
Right hemicolectomy for Dukes’ B carcinoma
two weeks later. (Note: this case is not included
in the original series of 89 patients.)
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have shown a prevalence of coeliac disease in iron
deficiency anaemia of 3›5%.1 One patient (case 7) had
developed a Dukes’ B ascending colon carcinoma at
follow up. A barium enema had originally been
advised but declined by the patient.
Although colonoscopy is accepted as the best way
to visualise the colon,12 less experienced workers may
fail to reach the caecum in up to half the cases.13›15
Double contrast barium enema may occasionally miss
colonic cancer, but these are usually in the sigmoid.16
We found that colonic cancers presenting with iron
deficiency anaemia were proximal to the splenic flex›
ure, suggesting that double contrast barium enema is
the investigation of choice, with colonoscopy reserved
for persistent or recurrent anaemia or when doubts
have been raised by the results of barium enema
examination.
We believe that the risk of missing colonic cancer
in patients with iron deficiency anaemia is sufficient to
justify colonic examination, if findings at gastroscopy
are benign. A cut off age of 40 would seem appropri›
ate in view of the evidence that almost all colonic can›
cers occur over the age of 50.7 Younger patients
without a family history or predisposing condition
should probably have colonic investigations for
persistent anaemia.
We thank the department of clinical audit at Chesterfield
Royal Hospital for their help. We are particularly grateful to
Christina Fielding for her advice during the planning of this
study and Jan Woodward for administrative support.
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A MEMORABLE PATIENT
Deceived by appearances
He was only a few years older than me, with a friendly
smile. His muscular physique and bronzed complexion
were, he told me proudly, the result of a working life spent
mainly in the fresh air. It was the second week of my first
house job, and he was the first patient on the list for minor
day case surgery. I was pleased to see a fit young
man—clerking him would be an easy job.
His medical history was brief; he had rarely consulted
a doctor. I chided him on his smoking habit and moved
on quickly to the physical examination. His chest was
clear, his cardiovascular system normal. His abdomen was
firm and difficult to palpate, but I was confident that it was
normal. A brief nervous system examination was similarly
unremarkable. As I felt for his apex beat, I had noticed the
Elastoplast stuck to his chest, just above his left nipple.
We chatted as he signed the consent form, and he
seemed eager to keep me talking. I was equally keen to
move on to the next patient, and tried not to feel irritated.
After all, I thought, he must be worried about his
operation. Eventually I made my escape, but he called me
back as I reached the end of his bed.
“Doc, would you like to take a look at this?” With a
nervous flourish, he pulled off the Elastoplast.
“I bet you’ve never seen a thing like this before, Doc.”
In fact I had, but only in textbooks. I felt as if I had
stepped off a cliff into nothingness; I could almost hear
the wind rushing past my ears. I struggled desperately to
control my features, and went to take a closer look.
The melanoma filled the area under the Elastoplast
and was obviously both malignant and advanced. A large,
jet black central nodule had a ragged surface, crusted with
dried blood. The margin was mottled with paler hues, and
was as irregular as an amoeba. A couple of small moles
nearby, which earlier I had barely noticed, now took on
the sinister appearance of satellite metastases.
My patient did not seem to find it strange that I
wanted to examine him again. With icy fingers and rising
nausea, I identified first the craggy mass of nodes in his
left axilla and then the suspicious lump above his left
clavicle. I still thought that his abdomen was probably
normal, but could I just feel a firm liver edge?
He could not remember when the mole had
appeared, but it had started to bleed at least two months
previously. He knew that he would be coming into
hospital soon, so why bother his general practitioner?
He never had his operation, of course. He was
transferred to the oncology unit at another hospital, and I
never saw him again. Years later, I am still grateful to him
for teaching me three invaluable lessons so early in my
medical career. Firstly, that the healthiest looking patient
may hide the most serious pathology. Secondly, that
however busy you are, take the time to look under any
dressings or clothing and always examine the whole
patient. Above all, remember that the patient who keeps
on talking may well have something important to tell you.
Jacqueline Napier is a pharmaceutical physician in west
Sussex
We welcome filler articles of up to 600 words on topics
such as A memorable patient, A paper that changed my practice,
My most unfortunate mistake, or any other piece conveying
instruction, pathos, or humour. If possible the article
should be supplied on a disk.
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